Why Neurocrine Biosciences, Inc.’s (NBIX) Stock Is Down 6.13%
As of Friday, July 31, Neurocrine Biosciences, Inc.’s NBIX share price has dipped by 6.13%, which has investors questioning if this is right time to buy.Michael Rose
Stock Evaluator: Neurocrine Biosciences, Inc. (NBIX)
Neurocrine Biosciences, Inc. NBIX
$166.80
-18.70
-10.08%
July 31, 2026 4:00:00 PM
EST
Volume: 4,584,218
After Hours: $120.37
0.15
|
0.12%
November 10, 2021 7:59 PM
EST
Volume: 72,713
USD
NASD | DELAYED PRICE
| SECTOR | INDUSTRY |
| Health Care | Biotechnology |
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Neurocrine Biosciences, Inc. discovers, develops, and commercialize pharmaceuticals for neurological, psychiatric, endocrine, and immunological disorders in the United States and internationally. The company’s products include INGREZZA for tardive dyskinesia and chorea associated with Huntington’s disease; Orilissa tablets for endometriosis; Oriahnn capsules to treat uterine fibroids; and CRENESSITY to treat congenital adrenal hyperplasia, as well as offers products under the name of ALKINDI and Efmody. Its product candidates in clinical development includes NBI-1076986 to treat movement disorders; Osavampator for inadequate response to treatment in major depressive disorder; NBI-1117568 for the treatment of schizophrenia and bipolar mania; NBI-1117567 for the treatment of Alzheimer’s disease; NBI 921355 for the treatment of epilepsy; NBIP-01435 for the treatment of congenital adrenal hyperplasia; NBIP-2118 for the treatment of obesity and related metabolic diseases; and NBI-1070770 to treat major depressive disorder; and NBI-1117570, NBI-1117567, NBI-1117569, NBI-1140675, and NBI-1065890 for neuropsychiatric and neurological conditions. The company also has license and collaboration agreements with Nxera Pharma UK Limited; Takeda Pharmaceutical Company Limited; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; Sanofi S.A.; Tanabe Pharma Corporation; and AbbVie Inc. The company was incorporated in 1992 and is headquartered in San Diego, California.
Commentary & Analysis
Why Neurocrine Biosciences, Inc.’s (NBIX) Stock Is Down 10.34%
As of Friday, July 31, Neurocrine Biosciences, Inc.’s NBIX share price has dipped by 10.34%, which has investors questioning if this is right time to buy.Omar Beirat
Is Neurocrine Biosciences, Inc. (NBIX) Overvalued?
We dive into why Neurocrine Biosciences, Inc. (NBIX) could be considered overvalued on 2026-07-21, based on AAII’s Value Score and Grade.Jenna Brashear
Why Neurocrine Biosciences, Inc.’s (NBIX) Stock Is Up 5.83%
As of Wednesday, June 03, Neurocrine Biosciences, Inc.’s NBIX share price has surged by 5.83%, which has investors questioning if this is right time to sell.Rosalio Madrigal
Which Is a Better Investment, Amgen Inc. or Neurocrine Biosciences, Inc. Stock?
Learn more about whether Amgen Inc. or Neurocrine Biosciences, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.Rosalio Madrigal
Financial Summary
| Share Statistics | NBIX | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $16,749.6 | $252.6 | 84% |
|
| Shares Out (Mil) | 103.4 | 52.3 | 63% |
|
| Institutional Ownership | 98.9% | 92.1% | 83% |
|
| Float (Mil) | 99.3 | 40.2 | 61% |
|
| Beta | 0.39 | 0.95 | 22% |
|
| Avg Daily Volume (000s) | 1,592 | 455 | 78% |
|
| Price Change (52-week) |
21.8% | 52.9% | 63% |
|
| Growth | NBIX | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 22.3% | 13.6% | 84% |
|
| Net Income (5yr) | 3.3% | (9.9%) | 44% |
|
| EPS (5yr) | 2.3% | 16.0% | 34 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | 43.2% | (15.6%) | 92% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 15 | 16 | 17 | |
| Current EPS | $1.960 | $9.925 | $12.241 | |
| Month Ago EPS | $2.167 | $10.184 | $12.597 | |
| # Rev Up | 0 | 1 | 1 | |
| # Rev Down | 1 | 0 | 0 | |
| Three Months Ago EPS | $1.946 | $9.634 | $12.715 | |
| Year/Year Chg | 2.6% | 112.5% | 240.2% | |
| Financials | NBIX | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $3,102 | $38 | 67% |
|
| Net Income (TTM) (Mil) | $669 | ($43) | 82% |
|
| EPS (TTM) | $6.706 | ($1.600) | 91% |
|
| Operating Cash Flow (TTM) (Mil) | $864 | ($31) | 79% |
|
| Net Cash Flow (TTM) (Mil) | $72 | $5 | 74% |
|
| Long-Term Debt (Q1) (Mil) | $406 | $5 | 57% |
|
| Enterprise Value (Q1) (Mil) | $17,799 | $180 | 82% |
|
| Valuation | NBIX | Industry Median |
Percentile (All Stocks) |
|
| P/B | 4.92 | 2.56 | 78% |
|
| P/E | 25.6 | 19.0 | 62% |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | 11.1 | 0.9 | 94% |
|
| Ratios | NBIX | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 64.6% | 63.8% | 77% |
|
| Net Margin | 20.9% | (67.3%) | 80% |
|
| ROA | 15.6% | (49.8%) | 94% |
|
| ROE | 22.5% | (55.5%) | 82% |
|
| Liabilities to Assets | 30.5% | 30.3% | 22% |
|
| F-Score | 7 | 3 | 84% |
|
Passing Stock Screens
As of 7/31/2026, from a list of 60 stock screening strategies,
GURU STRATEGY
Fisher (Philip) Screen
Factors: Value, Growth
A perspective on the evolution of the investment philosophy of a successful money manager who learned from his mistakes.
| Performance Since Inception: | 4.6% |
| +/- S&P 500: | -2.9 |
Passing Stocks
See All 3 Stocks (as of 7/31/2026)